Amgen’s Stelara biosimilar gets off to fast start
Sales of the company’s copycat to J&J’s blockbuster medicine reached $150 million in the first quarter, adding to a surge in revenue for Amgen's biosimilar business.
Sales of the company’s copycat to J&J’s blockbuster medicine reached $150 million in the first quarter, adding to a surge in revenue for Amgen's biosimilar business.
